MicroGenDX
Ken Perry has extensive work experience in various sales and business development roles. Ken is currently the Director of Business Development at MicroGenDX since May 2021. Prior to this, they held the position of Director of Sales at the same company from June 2019 to May 2021. Before joining MicroGenDX, Ken worked as the Senior Regional Director at the company from September 2014 to June 2019.
Ken also has experience as the Owner of Perry Medical LLC, a privately owned medical distributorship, where they sourced and distributed medical devices across the United States since December 2010.
Furthermore, Ken has worked as a Neurology Sales Specialist at Depomed, Inc., selling neurology products to neurologists and pain specialists from February 2013 to June 2016. Prior to this, they served as a Territory Sales Manager at BG Medical from December 2010 to February 2013.
Before transitioning into sales, Ken worked as a Certified Postal Consultant at Automated Business Solutions, Inc., managing the postage division across multiple states from November 2008 to November 2010. Ken also gained experience as an Area Sales Executive at Pitney Bowes from May 2006 to November 2008.
Ken Perry earned a Bachelor of Science - BS degree in Finance, General from Quinnipiac University, where they studied from 2001 to 2005.
This person is not in any teams
This person is not in any offices
MicroGenDX
MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX’s work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions. MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.